Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

784 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Incomplete inhibition of thromboxane biosynthesis by acetylsalicylic acid: determinants and effect on cardiovascular risk.
Eikelboom JW, Hankey GJ, Thom J, Bhatt DL, Steg PG, Montalescot G, Johnston SC, Steinhubl SR, Mak KH, Easton JD, Hamm C, Hu T, Fox KA, Topol EJ; Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management and Avoidance (CHARISMA) Investigators. Eikelboom JW, et al. Among authors: thom j. Circulation. 2008 Oct 21;118(17):1705-12. doi: 10.1161/CIRCULATIONAHA.108.768283. Epub 2008 Oct 6. Circulation. 2008. PMID: 18838564 Clinical Trial.
Randomized trial comparing 600- with 300-mg loading dose of clopidogrel in patients with non-ST elevation acute coronary syndrome undergoing percutaneous coronary intervention: results of the Platelet Responsiveness to Aspirin and Clopidogrel and Troponin Increment after Coronary intervention in Acute coronary Lesions (PRACTICAL) Trial.
Yong G, Rankin J, Ferguson L, Thom J, French J, Brieger D, Chew DP, Dick R, Eccleston D, Hockings B, Walters D, Whelan A, Eikelboom JW. Yong G, et al. Among authors: thom j. Am Heart J. 2009 Jan;157(1):60.e1-9. doi: 10.1016/j.ahj.2008.09.024. Am Heart J. 2009. PMID: 19081397 Clinical Trial.
Homocysteine-lowering treatment with folic acid, cobalamin, and pyridoxine does not reduce blood markers of inflammation, endothelial dysfunction, or hypercoagulability in patients with previous transient ischemic attack or stroke: a randomized substudy of the VITATOPS trial.
Dusitanond P, Eikelboom JW, Hankey GJ, Thom J, Gilmore G, Loh K, Yi Q, Klijn CJ, Langton P, van Bockxmeer FM, Baker R, Jamrozik K. Dusitanond P, et al. Among authors: thom j. Stroke. 2005 Jan;36(1):144-6. doi: 10.1161/01.STR.0000150494.91762.70. Epub 2004 Nov 29. Stroke. 2005. PMID: 15569860 Clinical Trial.
The tissue factor pathway in ischemic stroke.
Adams MJ, Thom J, Hankey GJ, Baker R, Gilmore G, Staton J, Eikelboom JW. Adams MJ, et al. Among authors: thom j. Blood Coagul Fibrinolysis. 2006 Oct;17(7):527-32. doi: 10.1097/01.mbc.0000245294.41774.06. Blood Coagul Fibrinolysis. 2006. PMID: 16988546
784 results